Treatment risk for cancer sufferers like Steve Jobs

By Admin
Steve Jobs has resigned as the CEO of Apple amid a seven year battle with a rare form of pancreatic cancer. The companys co-founder had been on three s...

Steve Jobs has resigned as the CEO of Apple amid a seven year battle with a rare form of pancreatic cancer.

The company’s co-founder had been on three stages of medical leave during his time at Apple, but yesterday said he could no longer meet his duties and expectations that came with being the CEO.

Health experts are now using the shock announcement as an opportunity to warn of the risks involved in treating patients with the rare form of pancreatic cancer suffered by Jobs.  


To read the latest edition of Healthcare Global, click here

In 2004 Jobs underwent a liver transplant to remove what was thought to be a neuroendocrine tumour, although he never spoke publicly of the reasons behind the operation.

However, medical professionals believe this is one of the riskiest and most complicated forms of treatment to remove the cancer, the news agency Reuters is reporting.

Reuters quoted Dr Simon Lo, a director of pancreatic and biliary diseases at Los Angeles’ Cedars-Sinai Medical Center, who said cancerous tumours returned in 75 percent of patients who had a liver transplant to remove them, two-five years after having the procedure.

Meanwhile, Lo added the drugs patients have to take after a liver transplant could make it harder for them to fight the cancer, which can easily spread to other organs in the body.

“Whenever you put patients on immunosuppressant medications, there's always a risk that it could take away natural resistance, so the cancer could grow faster,” Lo said.

He believes the former Apple Chief could be “confronting both the liver transplant related specific problems, as well as the cancer itself.”

Although there was no mention of his poor health in the letter of resignation that was released by Jobs yesterday, it is thought to be a contributing factor to his departure as he has been looking increasingly thin and frail in recent years. 


Featured Articles

TrueBinding’s antibody drugs fight Alzheimer’s Disease

Dongxu Sun, CEO at TrueBinding, shares how its research & antibody drug development is fighting illnesses such as Alzheimer’s Disease, stroke & more

Cardinal Health’s clinically integrated pharma supply chain

Peter Siavelis, SVP & General Manager, Health System and Provider Distribution & Services at Cardinal Health, discusses the integrated pharma supply chain

Healthcare Digital news roundup: digital healthcare & AI

This week in Healthcare Digital, we looked at digital skills for healthcare leaders, medical technology & acoustic AI used in digital cough monitoring

Hospitals must embrace IoMT device security


Mental health support for working women and mothers

Digital Healthcare

Digital evolution delivers better healthcare outcomes

Digital Healthcare